Chandan Healthcare Q2 PAT rises 281% on exceptional gain
Key highlights
- Chandan Healthcare reported Q2 FY27 consolidated revenue of Rs 58.0 crore, up 48% year-on-year.
- Consolidated Q2 FY27 PAT was Rs 18.2 crore versus Rs 4.8 crore a year earlier, up 281%.
- A Rs 10.2 crore exceptional gain aided Chandan Healthcare's reported Q2 FY27 profit.
- Chandan Healthcare reported half-year consolidated revenue of Rs 106.6 crore and PAT of Rs 24.9 crore.
powered by IRIS

Chandan Healthcare Limited reported consolidated profit after tax of Rs 18.2 crore for the quarter ended September 30, 2026, up 281% from Rs 4.8 crore a year earlier, aided by a Rs 10.2 crore exceptional gain. Consolidated revenue from operations rose 48% year-on-year to Rs 58.0 crore, making the exceptional item important when assessing the reported profit increase.
Know Chandan Healthcare inside out
Results, valuation, peers and who's buying, in one view.
What did Chandan Healthcare report for Q2 FY27?
Chandan Healthcare reported consolidated revenue from operations of Rs 58.0 crore in Q2 FY27, compared with Rs 39.2 crore in the corresponding quarter of the previous year. The company reported consolidated profit after tax of Rs 18.2 crore, against Rs 4.8 crore a year earlier.
The profit growth was materially supported by a Rs 10.2 crore exceptional gain. This means the reported year-on-year increase in net profit includes a non-operating or non-recurring component disclosed in the results summary, rather than being explained solely by the growth in revenue from operations.
The company also reported standalone net profit of Rs 18.55 crore for the quarter ended September 30, 2026, compared with Rs 7.28 crore in the same period last year. The standalone figure represented year-on-year growth of 154.81%, while the consolidated figures showed a larger percentage rise because of the lower comparison base and the exceptional gain.
How did the September-quarter results unfold?
The September-quarter results were considered by Chandan Healthcare's board at its meeting on November 14, 2026, for the period ended September 30, 2026. The company had previously intimated the exchange about the board meeting on September 7, 2026.
The reported half-year consolidated revenue was Rs 106.6 crore and half-year profit after tax was Rs 24.9 crore. These figures follow the June-quarter performance, when the company reported revenue of Rs 80.8 crore and profit of Rs 7.92 crore. The June-quarter revenue was 19.1% higher year-on-year, while profit was 27.9% higher.
Chandan Healthcare did not publish an earnings-call transcript for the September quarter. As a result, the available figures are based on the results statement and reported disclosures, rather than management guidance or commentary on future operating conditions.
A correction to the September 2026 results presentation was reported on November 15. The correction covered cash flow, tax and earnings per share, with no impact on total comprehensive income according to the disclosed information.
What are the key Q2 FY27 financial figures?
The key Q2 FY27 figures show revenue growth alongside a sharp increase in reported profit, with the exceptional gain being the central qualification for investors reviewing profitability. The available disclosures also show differences between standalone and consolidated reporting, which should not be treated as interchangeable measures.
The reported consolidated Q2 EBITDA was Rs 10.78 crore. A separate reported comparison listed Q2 operating profit at Rs 20.57 crore in the prior-year period, but the supplied disclosures contain different presentation formats and should be read alongside the underlying financial statements.
For the half year ended September 30, 2026, revenue from operations was also reported as Rs 106.61 crore in a separate disclosure. The prior figure cited there was Rs 156.65 crore for the full year ended March 31, 2026, rather than a comparable half-year period, so it does not provide a like-for-like growth comparison.
Got a follow-up? Ask IRIS
What does the result mean for Chandan Healthcare's operations?
The result indicates that Chandan Healthcare's consolidated revenue increased during the September quarter, while the reported profit was lifted by the exceptional gain. For assessing the operating trend, revenue growth and regular operating profitability are more directly comparable across periods than profit after tax that includes the disclosed exceptional item.
Chandan Healthcare operates a diagnostic network in North India, offering pathology and radiology testing services. The network had more than 500 operating franchise centres within a total network of more than 568 centres in mid-September. This operating footprint is relevant because the company derives its business from diagnostic services across its network rather than from a single facility.
In FY26, Chandan Healthcare reported consolidated total income of Rs 280.67 crore, EBITDA of Rs 56.84 crore and profit after tax of Rs 27.06 crore. In Q1 FY27, it reported total income of Rs 82.26 crore, EBITDA of Rs 20.98 crore and profit after tax of Rs 7.50 crore. These disclosures provide context for the September-quarter numbers, though quarterly and annual figures serve different comparison purposes.
The company allotted 650,000 equity shares at Rs 234 each on September 30, 2026, upon conversion of fully convertible warrants. The aggregate amount for this allotment was Rs 15.21 crore. The share issue is a separate capital-market development from the operating results.
Why should investors separate exceptional gains from operating performance?
Investors should separate exceptional gains from operating performance because Chandan Healthcare's Rs 10.2 crore exceptional gain contributed to its reported Q2 FY27 profit after tax of Rs 18.2 crore. Revenue growth of 48% provides evidence of expansion in the reported top line, but it does not by itself establish the extent of recurring profit growth.
The company adopted Ind AS from April 1, 2026, and comparative figures were restated according to the reported summary. Changes in accounting presentation can affect how investors compare figures across periods, making the restated comparatives and the notes to the financial statements relevant to any trend assessment.
Shareholding data for September 2026 showed promoter ownership of 48.42%, domestic institutional investor ownership of 5.06%, foreign institutional investor ownership of 0.00%, and public ownership of 46.52%. The number of shareholders stood at 1,688, compared with 1,591 in June 2026.
Conclusion
Chandan Healthcare's September-quarter consolidated results showed a 48% increase in revenue to Rs 58.0 crore and a 281% rise in reported PAT to Rs 18.2 crore. The disclosed Rs 10.2 crore exceptional gain is essential context, as it materially influenced the profit outcome while the company continued to report growth in its diagnostic-services revenue.
The next point to watch is the company's subsequent financial disclosure and whether it provides further detail on recurring profitability, operating cash flow and its diagnostic-network performance. Investors will also be able to assess future results against the restated Ind AS comparatives adopted from April 1, 2026.


